Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377819 | 0.83 | LMNA (0.53) | LMNAHSD11B1ALDH1A1 | |
| SCHEMBL8763630 | 0.79 | HSD11B1 (0.50) | LMNAHSD11B1ALDH1A1 | |
| SCHEMBL15413377 | 0.77 | AVPR1A (0.66) | ALDH1A1AVPR1A | |
| SCHEMBL889637 | 0.77 | HSD11B1 (0.56) | HSD11B1AVPR1A | |
| SCHEMBL14077010 | 0.75 | ALOX12 (0.57) | LMNA | |
| SCHEMBL14077013 | 0.75 | KDM4E (0.55) | HSD11B1ALDH1A1 | |
| SCHEMBL15026023 | 0.74 | HSD11B1 (0.36) | HSD11B1ALDH1A1AVPR1A | |
| SCHEMBL14804396 | 0.74 | ALDH1A1 (0.47) | HSD11B1ALDH1A1AVPR1A | |
| SCHEMBL22728144 | 0.72 | ALDH1A1 (0.40) | LMNAHSD11B1ALDH1A1 | |
| SCHEMBL14077046 | 0.71 | HSD11B1 (0.58) | LMNAHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163554-B1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | LMNA 2244/4885HSD11B1 307/4885METAP2 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.